Free tool
FAERS Monitor: Pataday Once Daily Relief
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021545 or its brand name (Pataday Once Daily Relief, Olopatadine Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
5,332
Serious
1,430
27% of reports
Hospitalization
807
Death reported
196
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- treatment failure1,934
- drug ineffective543
- eye irritation282
- vision blurred223
- eye discharge175
- eye pain164
- headache161
- ocular hyperaemia136
- eye pruritus135
- nausea129
- diarrhoea121
- fatigue114
- pruritus109
- condition aggravated108
- hypersensitivity107
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 6 |
| 2005 | 10 |
| 2006 | 5 |
| 2007 | 8 |
| 2008 | 17 |
| 2009 | 18 |
| 2010 | 26 |
| 2011 | 25 |
| 2012 | 24 |
| 2013 | 30 |
| 2014 | 29 |
| 2015 | 49 |
| 2016 | 82 |
| 2017 | 91 |
| 2018 | 131 |
| 2019 | 191 |
| 2020 | 1,941 |
| 2021 | 380 |
| 2022 | 408 |
| 2023 | 425 |
| 2024 | 431 |
| 2025 | 513 |
| 2026 | 492 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,048,827 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| treatment failureSignal | 1,934 | 94.3 | 90.9 | 174,893 |
| eye dischargeSignal | 175 | 67.6 | 58.3 | 11,222 |
| eye irritationSignal | 282 | 19.4 | 17.3 | 4,897 |
| eye pruritusSignal | 135 | 15.9 | 13.5 | 1,867 |
| eye painSignal | 164 | 11.5 | 9.9 | 1,561 |
| ocular hyperaemiaSignal | 136 | 11.3 | 9.6 | 1,270 |
| vision blurredSignal | 223 | 6.4 | 5.6 | 1,019 |
| hypersensitivitySignal | 107 | 2.3 | 1.9 | 76 |
| drug ineffective | 543 | 1.6 | 1.5 | 139 |
| condition aggravated | 108 | 1.4 | 1.2 | 12 |
| pruritus | 109 | 1.1 | 0.9 | 1 |
| headache | 161 | 1.0 | 0.9 | 0 |
| diarrhoea | 121 | 0.7 | 0.6 | 11 |
| nausea | 129 | 0.6 | 0.5 | 26 |
| fatigue | 114 | 0.6 | 0.5 | 36 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.